Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-07-11
2011-11-01
Bradley, Christina (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013500, C514S019200, C530S385000
Reexamination Certificate
active
08048856
ABSTRACT:
A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin, uncross-linked tetrameric hemoglobin, and plasma protein impurities effectively. Addition of N-acetyl cysteine after heat treatment and optionally before heat treatment maintains a low level of met-hemoglobin. The heat stable cross-linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal carcinoma and esophageal cancer. The inventive hemoglobin can also be used to prevent tumor metastasis and recurrence following surgical tumor excision. Further the inventive tetrameric hemoglobin can be administered to patients prior to chemotherapy and radiation treatment.
REFERENCES:
patent: 4543209 (1985-09-01), Tayot et al.
patent: 4598064 (1986-07-01), Walder
patent: 4600531 (1986-07-01), Walder
patent: 4831012 (1989-05-01), Estep
patent: 4987048 (1991-01-01), Shinozaki et al.
patent: 5084558 (1992-01-01), Rausch et al.
patent: 5189146 (1993-02-01), Hsia
patent: RE34271 (1993-06-01), Walder
patent: 5296465 (1994-03-01), Rausch et al.
patent: 5344393 (1994-09-01), Roth et al.
patent: 5439882 (1995-08-01), Feola et al.
patent: 5451205 (1995-09-01), Roth et al.
patent: 5591710 (1997-01-01), Hsia
patent: 5618919 (1997-04-01), Rausch et al.
patent: 5631219 (1997-05-01), Rosenthal et al.
patent: 5691453 (1997-11-01), Wertz et al.
patent: 5725839 (1998-03-01), Hsia
patent: 5741893 (1998-04-01), Hsia
patent: 5753616 (1998-05-01), Rausch et al.
patent: 5767089 (1998-06-01), Hsia
patent: 5789376 (1998-08-01), Hsia
patent: 5804561 (1998-09-01), Hsia
patent: 5807831 (1998-09-01), Hsia
patent: 5811005 (1998-09-01), Hsia
patent: 5814601 (1998-09-01), Winslow et al.
patent: 5817528 (1998-10-01), Bohm et al.
patent: 5817632 (1998-10-01), Hsia
patent: 5824781 (1998-10-01), Hsia
patent: 5840701 (1998-11-01), Hsia
patent: 5840851 (1998-11-01), Plomer et al.
patent: 5865784 (1999-02-01), Faithfull et al.
patent: 5895810 (1999-04-01), Light et al.
patent: 5905141 (1999-05-01), Rausch et al.
patent: 5955581 (1999-09-01), Rausch et al.
patent: 6007774 (1999-12-01), Faithfull et al.
patent: 6054427 (2000-04-01), Winslow
patent: 6127043 (2000-10-01), Lange
patent: 6160098 (2000-12-01), Kerwin
patent: 6242417 (2001-06-01), Gerber et al.
patent: 6270952 (2001-08-01), Cook et al.
patent: 6288027 (2001-09-01), Gawryl et al.
patent: 6323175 (2001-11-01), Hsia
patent: 6399357 (2002-06-01), Winge
patent: 6432918 (2002-08-01), Winslow
patent: 6486306 (2002-11-01), Winge
patent: 6506725 (2003-01-01), Rausch et al.
patent: RE38081 (2003-04-01), Faithfull et al.
patent: 6566504 (2003-05-01), Bhattacharya et al.
patent: 6599878 (2003-07-01), Rooney
patent: 6610832 (2003-08-01), Gawryl et al.
patent: 6709810 (2004-03-01), Cook et al.
patent: 6740139 (2004-05-01), Russell et al.
patent: 6747132 (2004-06-01), Privalle et al.
patent: 6844317 (2005-01-01), Winslow et al.
patent: 6894150 (2005-05-01), Tye
patent: 7038016 (2006-05-01), Talarico et al.
patent: 7101846 (2006-09-01), Winslow
patent: 7293985 (2007-11-01), Cook et al.
patent: 7411044 (2008-08-01), Avella et al.
patent: 7494974 (2009-02-01), Tye
patent: 7501499 (2009-03-01), Acharya et al.
patent: 7504377 (2009-03-01), Tye
patent: 7625862 (2009-12-01), Winslow et al.
patent: 7655392 (2010-02-01), Stassinopoulos
patent: 7759306 (2010-07-01), Simoni et al.
patent: 7932356 (2011-04-01), Wong et al.
patent: 2010/0209532 (2010-08-01), Dube et al.
patent: 2011/0129908 (2011-06-01), Owen et al.
Napolitano L.M., “Hemoglobin-based oxygen carriers: first, second or third generation? Human or bovine? Where are we now?”, Crit Care Clin. 25, 279-301 (2009).
Jiin-Yu Chen et al., “A review of blood substitutes; examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers”, Clinics 64(8), 803-813 (2009).
Larny ML et al., “Randomized Trial of Dlaspirin Cross-linked Hemoglobin Solution as an Alternative to Blood Transfusion after Cardiac Surgery”, Anesthesiology 92(3), 646-656 (2000).
Lois R. Manning et al., “Subunit dissociations in natural and recombinant hemoglobins”, Protein Science 5(4), 775-781 (1996).
Ronald Kluger et al., “Protein-protein coupling and its application to functional red cell substitutes”, Chem Commun (Camb). 46(8), 1194-1202 (2010).
Ronald Kluger, “Red cell substitutes from hemoglobin-do we start all over again?”, Current Opinion in Chemical Biology 14(4), 538-543 (2010).
Kenji Sampei et al., “Role of nitric oxide scavenging in vascular response to cell-free hemoglobin transfusion”, Am J Physiol Heart Circ Physiol 289(3), H1191-H1201 (2005).
Tao Hu et al., “Preparation and characterization of dimeric bovine hemoglobin tetramers”, Journal of Protein Chemistry 22(5), 411-416(2003).
Tao Hu et al., “PEGylation of Val-1(alpha) destabilizes the tetrameric structure of hemoglobin”, Biochemistry 48(3), 608-616 (2009).
Kim D Vandegriff et al., “Hemospan: design principles for a new class of oxygen therapeutic”, Artificial organs 33(2), 133-138 (2009).
Thoralf Kerner of al., “DCL-Hb for trauma patients with severe hemorrhagic shock; the European “On-Scene” multicenter study”, Intensive Care Medicine 29(3), 378-386 (2003).
Chad R. Haney et al., “Purification and chemical modifications of hemoglobin in developing hemoglobin based oxygen carriers”, Advanced Drug Delivery Reviews 40(3), 153-169 (2000).
Donat R. Spahn et al., “Artificial O2 carriers : Status in 2005”, Current pharmaceutical design 11(31), 4099-4114 (2005).
Andre F. Palmer et al., “Tangential flow filtration of hemoglobin”, Biotechnol Prog. 25(1), 189-199 (2009).
David C. Irwin et al., “Polymerized bovine hemoglobin decreases oxygen delivery during normoxia and acute hypoxia in the rat”, Am J Physiol Heart Circ Physiol 295(3), H1090-H1099 (2008).
Guoyong Sun et al, “Preparation of Ultrapure Bovine and Human Hemoglobin by Anion Exchange Chromatography”, J Chromatogr B Analyt Technol Biomed Life Sci. 867(1), 1-7 (2008).
Yiping Jia et al., “Effects of cross-linking end zero-link polymerization on oxygen transport and redox chemistry of bovine hemoglobin”, Biochimica et Biophysica Acta 1794(8), 1234-1242 (2009).
Cai Jin et al., “Chemically Modified Porcine Hemoglobins and Their Biological Properties”, Protein and Peptide Letters, vol. 11, No. 4, 353-360 (2004).
U.S. Appl. No. 12/821,214, Wong et al.
Ameri K et al., (2010) Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer; 102(3):561-9.
Morris Sherman. (2008) Recurrence of Hepatocellular Carcinoma. N Engl J Med; 359:2045-2047.
Van Der Bilt J. D. et al., (2005) Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology;42(1):165-75.
Ku Y. et al., (1999) Stimulation of haematogenous liver metastases by ischaemia-reperfusion in rats. Eur J Surg.; 165(8):801-7.
Yu et al., Cancer Treatment Reviews (2007) 33, pp. 757-761.
U.S. Appl. No. 13/013,850, Wong et al.
U.S. Appl. No. 13/083,639, Wong et al.
U.S. Appl. No. 13/097,183, Wong et al.
Raabe et al., Strahlentherapie und Onkologie, No. 11, 2005, pp. 730-737, “No Effect of the Hemoglobin Solution HBOC-201 on the Response of the Rat R1H Tumor to Fractionated Irradiation.”
Teicher (I) et al. I. J. Radiation Oncology, vol. 21, No. 4, pp. 969-975 1998, “Effect of Oxygen Level on the Enhancement of Tumor Response to Radiation by Perfluorochemical Emulsions of a Bovine Hemoglobin Preparation&#x
Kwok Sui Yi
Lau Sze Hang
Wong Bing Lou
Billion King, Ltd.
Bradley Christina
Burke Margaret
Ella Cheong Hong Kong
Yip Sam
LandOfFree
Treatment methods using a heat stable oxygen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment methods using a heat stable oxygen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment methods using a heat stable oxygen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4291470